
    
      This is a Phase I/II trial of elderly patients (> 70 years of age) with previously un-treated
      Advanced Stage Non-Squamous NSCLC with Stage IIIB (with malignant pleural effusion) and stage
      IV disease will be enrolled.

      Treatment Regimen:

      Premetrexed (Alimta™) 500 milligrams(mg)/Meter squared(m20 Intravenous(I.V.) Day 1 and Day
      15; Bevacizumab 10mg/Kilogram(Kg) I. V. Day 1 and Day 15; Erlotinib (Tarceva™) 150mg Per
      Orally(PO) Once Daily(QD) for 7 days starting day 2 and day 15; Repeat cycles every 28 days.

      All three drugs will be continued for two cycles after maximal response. After which patient
      will be maintained only on the Bevacizumab and Erlotinib until progression. If patient has
      stable disease after the first two cycles then patient will be given another two cycles with
      all three drugs before maintenance treatment with Bevacizumab and Erlotinib is initiated.
    
  